Latest Daily News

More Stories

July 23, 2018

In the following interview, the ASCO Daily News spoke with Stephen Leong, MD, of the University of Colorado School of Medicine, about immunotherapy’s progress in the field of gastrointestinal (GI) cancers and what he learned from abstracts presented during the 2018 ASCO Annual Meeting.

Read more

June 14, 2018

A high dose of a proton-pump inhibitor (PPI) combined with low-dose aspirin reduced the risk of death, esophageal adenocarcinoma (EA), or high-grade dysplasia (HGD) in patients with Barrett’s esophagus (BE) in a long-term, phase III randomized trial.

Read more

June 14, 2018

The combination of temozolomide and capecitabine resulted in improved progression-free and overall survival (Abstract 4004) compared with temozolomide monotherapy in patients with advanced pancreatic neuroendocrine tumors (NETs).

Read more

June 14, 2018

Neoadjuvant chemoradiotherapy resulted in improved outcomes compared with immediate surgery in patients with resectable and borderline resectable pancreatic cancer, according to results of the phase III PREOPANC trial (Abstract LBA4002).

Read more

June 14, 2018

Adjuvant chemotherapy with a modified FOLFIRINOX (mFOLFIRINOX) regimen was superior to gemcitabine with regard to disease-free, metastasis-free, and overall survival (OS) in patients with resected pancreatic cancer, according to a new randomized phase III trial.

Read more

June 14, 2018

The addition of oxaliplatin hyperthermic peritoneal chemotherapy (HIPEC) combined with cytoreductive surgery in patients with colorectal peritoneal carcinomatosis does not improve overall survival (OS) or recurrence-free survival (RFS).

Read more
May 14, 2018

Gallbladder cancer (GBC) is rare in Europe, the United States, and Canada. However, in some areas of South America, particularly in the Andean region of Chile, Ecuador, Peru, and Bolivia, the incidence and mortality rate are high.

Read more

May 13, 2018

National Comprehensive Cancer Network guidelines were recently updated to allow for a shorter duration of adjuvant chemotherapy for patients with low-risk stage III colon cancer.

Read more
June 4, 2017

In view of these findings, investigators in the IDEA collaboration reached a clinical consensus to recommend a risk-based approach to selecting adjuvant chemotherapy for stage III colon cancer. 

Read more

June 4, 2017

The BILCAP randomized study examined a cancer type for which “outcomes are poor—the 1- and 5-year survival rates are 22% and 9%, respectively,” said presenter Dr. John N. Primrose.

Read more
June 2, 2017

Here are some bite-sized articles from Saturday's ASCO Daily News coverage.

Read more
May 25, 2017

The Extended Education Session “Management of Complex Upper Gastrointestinal Cases: Implementation of Best Evidence,” to be held on June 2, will address these and other questions facing oncologists specializing in upper GI cancers.

Read more
May 25, 2017

The guideline, organized into 21 recommendations of how to use molecular biomarkers to diagnose and treat patients with colorectal cancer, represented an unprecedented collaboration between four organizations: CAP, ASCP, the Association for Molecular Pathology, and ASCO.

Read more
May 25, 2017

Patients with potentially curable pancreatic cancer should be treated with two medications—gemcitabine and capecitabine—after tumor resection, as long as there are no concerns about toxicity and chemotherapy.

Read more
April 7, 2017

The 2017 Gastrointestinal Cancers Symposium concluded another year of enlightening discourse, multidisciplinary education, and fruitful interaction among the more than 3,500 attendees.

Read more
June 6, 2016

Results from the FAST study demonstrated that IMAB362, an antibody against claudin, a tight junction protein, significantly prolonged median PFS and OS in gastric cancers. 

Read more
June 6, 2016

CRITICS reports on which adjuvant strategy, chemotherapy or chemoradiotherapy, provides better clinical outcomes for patients with resectable gastric cancer. What’s next for these patients? 

Read more

June 7, 2016

Phase III trial CALGB 80802 failed to demonstrate OS benefit with addition of doxorubicin to sorafenib in the first-line treatment of advanced HCC. The results contradict earlier phase II data, and suggest that the role of chemotherapy in advanced HCC could come to an end.

Read more

June 7, 2016

The benefits of palliative care for patients with advanced cancer and short life expectancy has been well established. New research suggests this care could improve quality of life and mood both among patients with lung and GI cancers early in the course of disease and their caregivers.

Read more
June 7, 2016

This Education Session offers insight into how past failures in gastric cancer, along with emerging genetic and molecular information, hold good solutions to solving the current treatment conundrum for this disease.

Read more